BALTIMORE, MD.—Epigenetic Data Sciences’ (EDS) Director of Research, Loretta Anderson will be speaking at the Alzheimer’s Disease International’s 33rd Conference 2018 (ADI) in Chicago, July 26 – 29, 2018. Alzheimer’s Disease International’s annual International Conference is the longest running and one of the largest international conferences on dementia. Their unique multi-disciplinary approach brings together all people with an interest in Alzheimer’s including researchers, scientists, people living with dementia, caregivers, as well as many others.
Our Director of Research, Loretta Anderson is excited to present groundbreaking work at this year’s ADI conference during their segment on Technology, Innovation, and Entrepreneurship. She will discuss the Neuro-Aging Division’s work on identifying novel therapeutic approaches to Alzheimer’s disease by targeting dysregulated epigenetic pathways. This work is the first step in identifying effective disease modifying treatments. Loretta will be on the main stage in the Plenary Hall, on Saturday July 28, 2018 at 5pm CDT. Her highly anticipated work, titled Innovative Software Platform for Targeting Dysregulated Epigenetic Pathways and Identifying Novel Therapeutic Approaches in Alzheimer’s Disease: A Comprehensive Approach will provide new insights into how we research disease-modifying treatments for Alzheimer’s disease.
With work beginning in 2014, Epigenetic Data Sciences is leading the fight against disease with cutting edge technologies through multiple disciplines. EDS is a pioneer in combining systems biology, epigenetics, and data science to study the abnormal gene expression critical for disease formation and progression. This knowledge is key to formulating plans to counter this dysregulation. With the Cancer and Neuro-Aging divisions up and running, EDS is on a mission to help those living with disease feel more confident in their self-care. For more information about EDS visit EpigeneticDS.com or follow us on social media – Twitter, LinkedIn, and Facebook.